Shares of Axsome Therapeutics, Inc. (AXSM) are rising more than 7% Monday morning after the company reported first-quarter results, above the Street view.
Axsome reported a net loss of $11.2 million or $0.26 per share for the first quarter, narrower than $39.6 million, or $1.03 per share loss for the comparable period last year, driven by increased revenue.
Analysts on average polled by Thomson-Reuters were expecting a loss of $1.04 per share.
Revenue for the quarter was $94.6 million compared with no revenue for the same quarter a year ago. The company had product sales of $28.6 million, license revenue of $65.7 million, and royalty revenue of $0.3 million. The consensus estimate was for $26.07 million.
Looking forward, Axsome believes that its current cash, along with the remaining committed capital from the $350 million term loan facility, is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.
AXSM, currently at $79.03, has traded in the range of $20.63-$82.85 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.